Factor XII: A novel target for safe prevention of thrombosis and inflammation

Journal of Internal Medicine

Volumn 278, Issue 6, 2015, Pages 571-585

  Kenne, E ^a   Nickel, K F ^a,b   Long, A T ^c   Fuchs, T A ^a,b   Stavrou, E X ^c   Stahl, F R ^b   Renne T ^a,b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anticoagulation; Coagulation; Factor XII; Polyphosphate; Thrombosis

Indexed keywords

ANTICOAGULANT AGENT; BLOCKING ANTIBODY; BLOCKING ANTIBODY 3F7; BLOOD CLOTTING FACTOR 12; BLOOD CLOTTING FACTOR 12A; BRADYKININ; HEPARIN; NUCLEIC ACID; POLYPHOSPHATE; PROTEIN AGGREGATE; UNCLASSIFIED DRUG;

ALLERGIC DISEASE; ANAPHYLAXIS; ARTERY THROMBOSIS; BLEEDING; BLOOD CLOTTING; BLOOD CLOTTING FACTOR 12 DEFICIENCY; CARDIOPULMONARY BYPASS; CHEMOTAXIS; HEMOSTASIS; HUMAN; INFLAMMATION; KALLIKREIN KININ SYSTEM; NONHUMAN; PRIORITY JOURNAL; REVIEW; SEPSIS; THROMBOSIS; VASODILATATION; VEIN THROMBOSIS; ANIMAL; BLOOD; CHEMICALLY INDUCED; DRUG DEVELOPMENT; DRUG EFFECTS; HEMORRHAGE; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; ANTICOAGULANTS; BLOOD COAGULATION; DRUG DISCOVERY; FACTOR XIIA; HEMORRHAGE; HUMANS; INFLAMMATION; THROMBOSIS;

EID: 84955171842     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/joim.12430     Document Type: Review

References (132)

1. Mackman N. Triggers, targets and treatments for thrombosis. Nature 2008; 451: 914-8.
2. Renne T, Schmaier AH, Nickel KF, Blomback M, Maas C. In vivo roles of factor XII. Blood 2012; 120: 4296-303.
3. Pauer HU, Renne T, Hemmerlein B et al. Targeted deletion of murine coagulation factor XII gene-a model for contact phase activation in vivo. Thromb Haemost 2004; 92: 503-8.
4. Iwaki T, Castellino FJ. Plasma levels of bradykinin are suppressed in factor XII-deficient mice. Thromb Haemost 2006; 95: 1003-10.
5. Renne T, Pozgajova M, Gruner S et al. Defective thrombus formation in mice lacking coagulation factor XII. J Exp Med 2005; 202: 271-81.
6. Kleinschnitz C, Stoll G, Bendszus M et al. Targeting coagulation factor XII provides protection from pathological thrombosis in cerebral ischemia without interfering with hemostasis. J Exp Med 2006; 203: 513-8.
7. Muller F, Mutch NJ, Schenk WA et al. Platelet polyphosphates are proinflammatory and procoagulant mediators in vivo. Cell 2009; 139: 1143-56.
8. Revenko AS, Gao D, Crosby JR et al. Selective depletion of plasma prekallikrein or coagulation factor XII inhibits thrombosis in mice without increased risk of bleeding. Blood 2011; 118: 5302-11.
9. Hagedorn I, Schmidbauer S, Pleines I et al. Factor XIIa inhibitor recombinant human albumin Infestin-4 abolishes occlusive arterial thrombus formation without affecting bleeding. Circulation 2010; 121: 1510-7.
10. Chen JW, Figueiredo JL, Wojtkiewicz GR et al. Selective factor XIIa inhibition attenuates silent brain ischemia: application of molecular imaging targeting coagulation pathway. JACC Cardiovasc Imaging 2012; 5: 1127-38.
11. Decrem Y, Rath G, Blasioli V et al. Ir-CPI, a coagulation contact phase inhibitor from the tick Ixodes ricinus, inhibits thrombus formation without impairing hemostasis. J Exp Med 2009; 206: 2381-95.
12. von Bruhl ML, Stark K, Steinhart A et al. Monocytes, neutrophils, and platelets cooperate to initiate and propagate venous thrombosis in mice in vivo. J Exp Med 2012; 209: 819-35.
13. Benz PM, Blume C, Moebius J et al. Cytoskeleton assembly at endothelial cell-cell contacts is regulated by alphaII-spectrin-VASP complexes. J Cell Biol 2008; 180: 205-19.
14. Benz PM, Blume C, Seifert S et al. Differential VASP phosphorylation controls remodeling of the actin cytoskeleton. J Cell Sci 2009; 122: 3954-65.
15. Bjorkqvist J, Jamsa A, Renne T. Plasma kallikrein: the bradykinin-producing enzyme. Thromb Haemost 2013; 110: 399-407.
16. Brown NJ, Gainer JV, Stein CM, Vaughan DE. Bradykinin stimulates tissue plasminogen activator release in human vasculature. Hypertension 1999; 33: 1431-5.
17. Kaplan AP, Austen KF. The fibrinolytic pathway of human plasma. Isolation and characterization of the plasminogen proactivator. J Exp Med 1972; 136: 1378-93.
18. Ghebrehiwet B, Silverberg M, Kaplan AP. Activation of the classical pathway of complement by Hageman factor fragment. J Exp Med 1981; 153: 665-76.
19. Bjorkqvist J, Sala-Cunill A, Renne T. Hereditary angioedema: a bradykinin-mediated swelling disorder. Thromb Haemost 2013; 109: 368-74.
20. Cichon S, Martin L, Hennies HC et al. Increased activity of coagulation factor XII (hageman factor) causes hereditary angioedema Type III. Am J Hum Genet 2006; 79: 1098-104.
21. Bjorkqvist J, de Maat S, Lewandrowski U et al. Defective glycosylation of coagulation factor XII causes hereditary angioedema type III. J Clin Invest 2015; 125: 3135-46.
22. Siebeck M, Cheronis JC, Fink E et al. Dextran sulfate activates contact system and mediates arterial hypotension via B2 kinin receptors. J Appl Physiol 1994; 77: 2675-80.
23. Bjorkqvist J, Lecher B, Maas C, Renne T. Zinc-dependent contact system activation induces vascular leakage and hypotension in rodents. Biol Chem 2013; 394: 1195-204.
24. Pan J, Qian Y, Zhou X, Lu H, Ramacciotti E, Zhang L. Chemically oversulfated glycosaminoglycans are potent modulators of contact system activation and different cell signaling pathways. J Biol Chem 2010; 285: 22966-75.
25. Guerrini M, Beccati D, Shriver Z et al. Oversulfated chondroitin sulfate is a contaminant in heparin associated with adverse clinical events. Nat Biotechnol 2008; 26: 669-75.
26. McMahon AW, Pratt RG, Hammad TA et al. Description of hypersensitivity adverse events following administration of heparin that was potentially contaminated with oversulfated chondroitin sulfate in early 2008. Pharmacoepidemiol Drug Saf 2010; 19: 921-33.
27. Kishimoto TK, Viswanathan K, Ganguly T et al. Contaminated heparin associated with adverse clinical events and activation of the contact system. N Engl J Med 2008; 358: 2457-67.
28. Forsberg E, Pejler G, Ringvall M et al. Abnormal mast cells in mice deficient in a heparin-synthesizing enzyme. Nature 1999; 400: 773-6.
29. Hojima Y, Cochrane CG, Wiggins RC, Austen KF, Stevens RL. In vitro activation of the contact (Hageman factor) system of plasma by heparin and chondroitin sulfate E. Blood 1984; 63: 1453-9.
30. Brunnee T, Reddigari SR, Shibayama Y, Kaplan AP, Silverberg M. Mast cell derived heparin activates the contact system: a link to kinin generation in allergic reactions. Clin Exp Allergy 1997; 27: 653-63.
31. Oschatz C, Maas C, Lecher B et al. Mast cells increase vascular permeability by heparin-initiated bradykinin formation in vivo. Immunity 2011; 34: 258-68.
32. Renne T, Müller-Esterl W. Cell surface-associated chondroitin sulfate proteoglycans bind contact phase factor H-kininogen. FEBS Lett 2001; 500: 36-40.
33. Jonasson O, Becker EL. Release of kallikrein from guinea pig lung during anaphylaxis. J Exp Med 1966; 123: 509-22.
34. Sala-Cunill A, Bjorkqvist J, Senter R et al. Plasma contact system activation drives anaphylaxis in severe mast cell-mediated allergic reactions. J Allergy Clin Immunol 2015; 135: 1031-43.
35. Jeske W, Lojewski B, Walenga JM, Hoppensteadt D, Ahsan A, Fareed J. Biochemical and pharmacologic profile of low molecular weight heparin (LU 47311, Clivarin). Semin Thromb Hemost 1993; 19(Suppl 1): 229-40.
36. Smith LA, Harkness M. A case of two adverse reactions. Postgrad Med J 2004; 80: 484-6.
37. Maas C, Govers-Riemslag JW, Bouma B et al. Misfolded proteins activate factor XII in humans, leading to kallikrein formation without initiating coagulation. J Clin Invest 2008; 118: 3208-18.
38. Zamolodchikov D, Chen ZL, Conti BA, Renne T, Strickland S. Activation of the factor XII-driven contact system in Alzheimer's disease patient and mouse model plasma. Proc Natl Acad Sci U S A 2015; 112: 4068-73.
39. Kannemeier C, Shibamiya A, Nakazawa F et al. Extracellular RNA constitutes a natural procoagulant cofactor in blood coagulation. Proc Natl Acad Sci U S A 2007; 104: 6388-93.
40. Vu TT, Zhou J, Leslie BA et al. Arterial thrombosis is accelerated in mice deficient in histidine-rich glycoprotein. Blood 2015; 125: 2712-9.
41. Simsekyilmaz S, Cabrera-Fuentes HA, Meiler S et al. Role of extracellular RNA in atherosclerotic plaque formation in mice. Circulation 2014; 129: 598-606.
42. Fuchs TA, Brill A, Wagner DD. Neutrophil extracellular trap (NET) impact on deep vein thrombosis. Arterioscler Thromb Vasc Biol 2012; 32: 1777-83.
43. Oehmcke S, Morgelin M, Herwald H. Activation of the human contact system on neutrophil extracellular traps. J Innate Immun 2009; 1: 225-30.
44. Gould TJ, Vu TT, Swystun LL et al. Neutrophil extracellular traps promote thrombin generation through platelet-dependent and platelet-independent mechanisms. Arterioscler Thromb Vasc Biol 2014; 34: 1977-84.
45. Castaldi PA, Larrieu MJ, Caen J. Availability of platelet Factor 3 and activation of factor XII in thrombasthenia. Nature 1965; 207: 422-4.
46. Back J, Sanchez J, Elgue G, Ekdahl KN, Nilsson B. Activated human platelets induce factor XIIa-mediated contact activation. Biochem Biophys Res Commun 2010; 391: 11-7.
47. Johne J, Blume C, Benz PM et al. Platelets promote coagulation factor XII-mediated proteolytic cascade systems in plasma. Biol Chem 2006; 387: 173-8.
48. Walsh PN, Griffin JH. Contributions of human platelets to the proteolytic activation of blood coagulation factors XII and XI. Blood 1981; 57: 106-18.
49. Latour JG, McKay DG, Parrish MH. Activation of Hageman factor by cardiac arrest. Thromb Diath Haemorrh 1972; 27: 543-53.
50. Walsh PN. The role of platelets in the contact phase of blood coagulation. Br J Haematol 1972; 22: 237-54.
51. Van Der Meijden PE, Van Schilfgaarde M, Van Oerle R, Renne T, ten Cate H, Spronk HM. Platelet- and erythrocyte-derived microparticles trigger thrombin generation via factor XIIa. J Thromb Haemost 2012; 10: 1355-62.
52. Kornberg A. Inorganic polyphosphate: a molecule of many functions. Prog Mol Subcell Biol 1999; 23: 1-18.
53. Ruiz FA, Lea CR, Oldfield E, Docampo R. Human platelet dense granules contain polyphosphate and are similar to acidocalcisomes of bacteria and unicellular eukaryotes. J Biol Chem 2004; 279: 44250-7.
54. Rao NN, Gomez-Garcia MR, Kornberg A. Inorganic polyphosphate: essential for growth and survival. Annu Rev Biochem 2009; 78: 605-47.
55. Smith SA, Mutch NJ, Baskar D, Rohloff P, Docampo R, Morrissey JH. Polyphosphate modulates blood coagulation and fibrinolysis. Proc Natl Acad Sci U S A 2006; 103: 903-8.
56. Semeraro F, Ammollo CT, Morrissey JH et al. Extracellular histones promote thrombin generation through platelet-dependent mechanisms: involvement of platelet TLR2 and TLR4. Blood 2011; 118: 1952-61.
57. Smith SA, Choi SH, Davis-Harrison R et al. Polyphosphate exerts differential effects on blood clotting, depending on polymer size. Blood 2010; 116: 4353-9.
58. Puy C, Tucker EI, Wong ZC et al. Factor XII promotes blood coagulation independent of factor XI in the presence of long-chain polyphosphates. J Thromb Haemost 2013; 11: 1341-52.
59. Ghosh S, Shukla D, Suman K et al. Inositol hexakisphosphate kinase 1 maintains hemostasis in mice by regulating platelet polyphosphate levels. Blood 2013; 122: 1478-86.
60. Nickel KF, Romquist G, Langer F et al. The polyphosphate-factor XII pathway drives coagulation in prostate cancer-associated thrombosis. Blood 2015; pii: blood-2015-01-622811
61. Morrissey JH, Smith SA. Comment on Faxalv et al. "Putting polyphosphates to the test: evidence against platelet-induced activation of factor XII". Blood 2013; 122: http://www.bloodjournal.org/content/122/23/3818.e-letters.
62. Nickel KF, Spronk HM, Mutch NJ, Renne T. Time-dependent degradation and tissue factor addition mask the ability of platelet polyphosphates in activating factor XII-mediated coagulation. Blood 2013; 122: 3847-9.
63. Engel R, Brain CM, Paget J, Lionikiene AS, Mutch NJ. Single-chain factor XII exhibits activity when complexed to polyphosphate. J Thromb Haemost 2014; 12: 1513-22.
64. Alvarenga PH, Xu X, Oliveira F et al. Novel family of insect salivary inhibitors blocks contact pathway activation by binding to polyphosphate, heparin, and dextran sulfate. Arterioscler Thromb Vasc Biol 2013; 33: 2759-70.
65. Travers RJ, Shenoi RA, Kalathottukaren MT, Kizhakkedathu JN, Morrissey JH. Nontoxic polyphosphate inhibitors reduce thrombosis while sparing hemostasis. Blood 2014; 124: 3183-90.
66. Faxalv L, Boknas N, Strom JO et al. Putting polyphosphates to the test: evidence against platelet-induced activation of factor XII. Blood 2013; 122: 3818-24.
67. Nielsen VG, Cohen BM, Cohen E. Effects of coagulation factor deficiency on plasma coagulation kinetics determined via Thrombelastography: critical roles of fibrinogen and factors II, VII, X and XII. Acta Anaesthesiol Scand 2005; 49: 222-31.
68. Pivalizza EG. Perioperative use of the Thrombelastograph in patients with inherited bleeding disorders. J Clin Anesth 2003; 15: 366-70.
69. Hebbard CF, Smith SA, Breitenfeld RM, et al. Polyphosphate decay in serum is chemical, not enzymatic. J Thromb Haemost 2015; 13: 915.
70. Butenas S, Mann KG. Active tissue factor in blood? Nat Med 2004; 10: 1155-6.
71. Choi SH, Smith SA, Morrissey JH. Polyphosphate is a cofactor for the activation of factor XI by thrombin. Blood 2011; 118: 6963-70.
72. Montilla M, Hernandez-Ruiz L, Garcia-Cozar FJ, Alvarez-Laderas I, Rodriguez-Martorell J, Ruiz FA. Polyphosphate binds to human von Willebrand factor in vivo and modulates its interaction with glycoprotein Ib. J Thromb Haemost 2012; 10: 2315-23.
73. Smith SA, Morrissey JH. Polyphosphate enhances fibrin clot structure. Blood 2008; 112: 2810-6.
74. Mutch NJ, Myles T, Leung LL, Morrissey JH. Polyphosphate binds with high affinity to exosite II of thrombin. J Thromb Haemost 2010; 8: 548-55.
75. Wat JM, Foley JH, Krisinger MJ et al. Polyphosphate suppresses complement via the terminal pathway. Blood 2014; 123: 768-76.
76. Xu J, Zhang X, Pelayo R et al. Extracellular histones are major mediators of death in sepsis. Nat Med 2009; 15: 1318-21.
77. Ekaney ML, Otto GP, Sossdorf M et al. Impact of plasma histones in human sepsis and their contribution to cellular injury and inflammation. Crit Care 2014; 18: 543.
78. Dinarvand P, Hassanian SM, Qureshi SH et al. Polyphosphate amplifies proinflammatory responses of nuclear proteins through interaction with receptor for advanced glycation end products and P2Y1 purinergic receptor. Blood 2014; 123: 935-45.
79. Frank RD, Mueller U, Lanzmich R, Floege J. Factor XII activation markers do not reflect FXII dependence of thrombin generation induced by polyvinylchloride. J Mater Sci Mater Med 2013; 24: 2561-6.
80. Svensson M, Friberger P, Lundstrom O, Stegmayr B. Activation of FXII during haemodialysis. Scand J Clin Lab Invest 1996; 56: 649-52.
81. Alturfan AA, Eralp L, Emekli N. Investigation of inflammatory and hemostatic parameters in female patients undergoing total knee arthroplasty surgery. Inflammation 2008; 31: 414-21.
82. Cugno M, Nussberger J, Biglioli P, Alamanni F, Coppola R, Agostoni A. Increase of bradykinin in plasma of patients undergoing cardiopulmonary bypass: the importance of lung exclusion. Chest 2001; 120: 1776-82.
83. de Vroege R, Huybregts R, van Oeveren W et al. The impact of heparin-coated circuits on hemodynamics during and after cardiopulmonary bypass. Artif Organs 2005; 29: 490-7.
84. Yau JW, Stafford AR, Liao P, Fredenburgh JC, Roberts R, Weitz JI. Mechanism of catheter thrombosis: comparison of the antithrombotic activities of fondaparinux, enoxaparin, and heparin in vitro and in vivo. Blood 2011; 118: 6667-74.
85. Yau JW, Stafford AR, Liao P et al. Corn trypsin inhibitor coating attenuates the prothrombotic properties of catheters in vitro and in vivo. Acta Biomater 2012; 8: 4092-100.
86. Yau JW, Liao P, Fredenburgh JC et al. Selective depletion of factor XI or factor XII with antisense oligonucleotides attenuates catheter thrombosis in rabbits. Blood 2014; 123: 2102-7.
87. Schmaier AH. Extracorporeal circulation without bleeding. Sci Transl Med 2014; 6: 222 fs7.
88. Kenne E, Renne T. Factor XII: a drug target for safe interference with thrombosis and inflammation. Drug Discov Today 2014; 19: 1459-64.
89. Larsson M, Rayzman V, Nolte MW et al. A factor XIIa inhibitory antibody provides thromboprotection in extracorporeal circulation without increasing bleeding risk. Sci Transl Med 2014; 6: 222ra17.
90. Cheng Q, Tucker EI, Pine MS et al. A role for factor XIIa-mediated factor XI activation in thrombus formation in vivo. Blood 2010; 116: 3981-9.
91. Matafonov A, Leung PY, Gailani AE et al. Factor XII inhibition reduces thrombus formation in a primate thrombosis model. Blood 2014; 123: 1739-46.
92. Leung PY, Hurst S, Berny-Lang MA et al. Inhibition of factor XII-mediated activation of factor XI provides protection against experimental acute ischemic stroke in mice. Transl Stroke Res 2012; 3: 381-9.
93. Kuijpers MJ, van der Meijden PE, Feijge MA et al. Factor XII regulates the pathological process of thrombus formation on ruptured plaques. Arterioscler Thromb Vasc Biol 2014; 34: 1674-80.
94. Wilner GD, Nossel HL, LeRoy EC. Activation of Hageman factor by collagen. J Clin Invest 1968; 47: 2608-15.
95. van der Meijden PE, Munnix IC, Auger JM et al. Dual role of collagen in factor XII-dependent thrombus formation. Blood 2009; 34: 1674-80.
96. van Montfoort ML, Kuijpers MJ, Knaup VL et al. Factor XI regulates pathological thrombus formation on acutely ruptured atherosclerotic plaques. Arterioscler Thromb Vasc Biol 2014; 34: 1668-73.
97. Reininger AJ, Bernlochner I, Penz SM et al. A 2-step mechanism of arterial thrombus formation induced by human atherosclerotic plaques. J Am Coll Cardiol 2010; 55: 1147-58.
98. Konings J, Govers-Riemslag JW, Philippou H et al. Factor XIIa regulates the structure of the fibrin clot independently of thrombin generation through direct interaction with fibrin. Blood 2011; 118: 3942-51.
99. Dahlback B. Coagulation and inflammation-close allies in health and disease. Semin Immunopathol 2012; 34: 1-3.
100. Wollein Waldetoft K, Svensson L, Morgelin M et al. Streptococcal surface proteins activate the contact system and control its antibacterial activity. J Biol Chem 2012; 287: 25010-8.
101. Holm K, Frick IM, Bjorck L, Rasmussen M. Activation of the contact system at the surface of Fusobacterium necrophorum represents a possible virulence mechanism in Lemierre's syndrome. Infect Immun 2011; 79: 3284-90.
102. Murphy EC, Morgelin M, Cooney JC, Frick IM. Interaction of Bacteroides fragilis and Bacteroides thetaiotaomicron with the kallikrein-kinin system. Microbiology 2011; 157: 2094-105.
103. Morrison DC, Cochrane CG. Direct evidence for Hageman factor (factor XII) activation by bacterial lipopolysaccharides (endotoxins). J Exp Med 1974; 140: 797-811.
104. Nickel KF, Renne T. Crosstalk of the plasma contact system with bacteria. Thromb Res 2012; 130(Suppl 1): S78-83.
105. Nordahl EA, Rydengard V, Morgelin M, Schmidtchen A. Domain 5 of high molecular weight kininogen is antibacterial. J Biol Chem 2005; 280: 34832-9.
106. Frick IM, Akesson P, Herwald H et al. The contact system - a novel branch of innate immunity generating antibacterial peptides. EMBO J 2006; 25: 5569-78.
107. Kaman WE, Wolterink AF, Bader M, Boele LC, van der Kleij D. The bradykinin B2 receptor in the early immune response against Listeria infection. Med Microbiol Immunol 2009; 198: 39-46.
108. Persson K, Morgelin M, Lindbom L, Alm P, Bjorck L, Herwald H. Severe lung lesions caused by Salmonella are prevented by inhibition of the contact system. J Exp Med 2000; 192: 1415-24.
109. Iwaki T, Cruz-Topete D, Castellino FJ. A complete factor XII deficiency does not affect coagulopathy, inflammatory responses, and lethality, but attenuates early hypotension in endotoxemic mice. J Thromb Haemost 2008; 6: 1993-5.
110. Jansen PM, Pixley RA, Brouwer M et al. Inhibition of factor XII in septic baboons attenuates the activation of complement and fibrinolytic systems and reduces the release of interleukin-6 and neutrophil elastase. Blood 1996; 87: 2337-44.
111. Pixley RA, De La Cadena R, Page JD et al. The contact system contributes to hypotension but not disseminated intravascular coagulation in lethal bacteremia. In vivo use of a monoclonal anti-factor XII antibody to block contact activation in baboons. J Clin Invest 1993; 91: 61-8.
112. Scharfstein J, Schmitz V, Morandi V et al. Host cell invasion by Trypanosoma cruzi is potentiated by activation of bradykinin B(2) receptors. J Exp Med 2000; 192: 1289-300.
113. Taylor SL, Wahl-Jensen V, Copeland AM, Jahrling PB, Schmaljohn CS. Endothelial cell permeability during hantavirus infection involves factor XII-dependent increased activation of the kallikrein-kinin system. PLoS Pathog 2013; 9: e1003470.
114. Ratnoff OD, Colopy JE. A familial hemorrhagic trait associated with a deficiency of a clot-promoting fraction of plasma. J Clin Invest 1955; 34: 602-13.
115. Ratnoff OD, Busse RJ, Sheon RP. The demise of John Hageman. N Engl J Med 1968; 279: 760-1.
116. Siegerink B, Govers-Riemslag JW, Rosendaal FR, Ten Cate H, Algra A. Intrinsic coagulation activation and the risk of arterial thrombosis in young women: results from the Risk of Arterial Thrombosis in relation to Oral contraceptives (RATIO) case-control study. Circulation 2010; 122: 1854-61.
117. Siegerink B, Rosendaal FR, Algra A. Antigen levels of coagulation factor XII, coagulation factor XI and prekallikrein, and the risk of myocardial infarction and ischemic stroke in young women. J Thromb Haemost 2014; 12: 606-13.
118. Doggen CJ, Rosendaal FR, Meijers JC. Levels of intrinsic coagulation factors and the risk of myocardial infarction among men: opposite and synergistic effects of factors XI and XII. Blood 2006; 108: 4045-51.
119. Bach J, Endler G, Winkelmann BR et al. Coagulation factor XII (FXII) activity, activated FXII, distribution of FXII C46T gene polymorphism and coronary risk. J Thromb Haemost 2008; 6: 291-6.
120. Endler G, Marsik C, Jilma B, Schickbauer T, Quehenberger P, Mannhalter C. Evidence of a U-shaped association between factor XII activity and overall survival. J Thromb Haemost 2007; 5: 1143-8.
121. Key NS. Epidemiologic and clinical data linking factors XI and XII to thrombosis. Hematology Am Soc Hematol Educ Program 2014; 2014: 66-70.
122. Ponitz V, Brugger-Andersen T, Pritchard D et al. Activated factor XII type A predicts long-term mortality in patients admitted with chest pain. J Thromb Haemost 2009; 7: 277-87.
123. Ponitz V, Pritchard D, Grundt H, Mehus MB, Nilsen DW. Changes of plasma activated Factor XII type A (XIIaA) concentrations following percutaneous coronary intervention (PCI). J Thromb Thrombolysis 2007; 24: 131-5.
124. Miller GJ, Esnouf MP, Burgess AI, Cooper JA, Mitchell JP. Risk of coronary heart disease and activation of factor XII in middle-aged men. Arterioscler Thromb Vasc Biol 1997; 17: 2103-6.
125. Salomon O, Steinberg DM, Koren-Morag N, Tanne D, Seligsohn U. Reduced incidence of ischemic stroke in patients with severe factor XI deficiency. Blood 2008; 111: 4113-7.
126. Salomon O, Steinberg DM, Zucker M, Varon D, Zivelin A, Seligsohn U. Patients with severe factor XI deficiency have a reduced incidence of deep-vein thrombosis. Thromb Haemost 2011; 105: 269-73.
127. Asakai R, Chung DW, Davie EW, Seligsohn U. Factor XI deficiency in Ashkenazi Jews in Israel. N Engl J Med 1991; 325: 153-8.
128. Buller HR, Bethune C, Bhanot S et al. Factor XI antisense oligonucleotide for prevention of venous thrombosis. N Engl J Med 2015; 372: 232-40.
129. Flaumenhaft R. Making (anti)sense of factor XI in thrombosis. N Engl J Med 2015; 372: 277-8.
130. Renne T, Gailani D. Role of Factor XII in hemostasis and thrombosis: clinical implications. Expert Rev Cardiovasc Ther 2007; 5: 733-41.
131. Pixley RA, DeLa Cadena RA, Page JD et al. Activation of the contact system in lethal hypotensive bacteremia in a baboon model. Am J Pathol 1992; 140: 897-906.
132. Gao BB, Clermont A, Rook S et al. Extracellular carbonic anhydrase mediates hemorrhagic retinal and cerebral vascular permeability through prekallikrein activation. Nat Med 2007; 13: 181-8.